CGEM - Cullinan Therapeutics, Inc. News

Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the an

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion st

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises

Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-

Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Pr

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

seekingalpha.com

Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGF

Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform

seekingalpha.com

Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in

Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-9

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targe

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutiona

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmu

New and updated clinical data to be presented from over 30 patients across systemic lupus erythemato

The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acu

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

$Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia$

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Enga

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to ad

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating p

$Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress$

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoi

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl

gurufocus.com

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the an

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Othe

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $38 Price Target

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and mainta

seekingalpha.com

Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst

Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $30

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a

Cullinan Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

https://www.sec.gov/Archives/edgar/data/1789972/000119312526183596/d587157ds3asr.htm

Taiho, Cullinan Announce Zipalertinib NDA Accepted By FDA For NSCLC Harboring EGFR ex20ins Mutations

NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meanin

businesswire.com

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceuti

Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Lee

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Cullinan Therapeutics: Q4 Earnings Insights

Cullinan Therapeutics Q4 EPS $(0.77) Beats $(0.82) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the an

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financ

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA conf

Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Confe

Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the com

Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of t

Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cull

Citigroup Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $33

Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) wit

Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $3

Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a B

HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform a

Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving High

Cullinan Therapeutics Reports CLN-049 Monotherapy Efficacy With Multiple Complete Responses And Dura

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encou

Cullinan Therapeutics Says FDA Granted Fast Track Designation To CLN-049 For Treatment Of Relapsed/R

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients